Literature DB >> 798729

Clofazimine binding studies with deoxyribonucleic acid.

N E Morrison, G M Marley.   

Abstract

1. The antileprosy drug, clofazimine, formed stable complexes with DNA and transfer RNA. A quantitative study was made of the spectral red shifts that occurred when clofazimine interacted with DNA. The red shift appeared specific for clofazimine binding to nucleic acid polymers. 2. The degree of clofazimine interaction with DNA was related to the G+C content of the DNA strand. As compared to the human strand, clofazimine interacted with the mycobacterial strand to give a larger red shift which was consistent with the increased G+C content of mycobacterial DNA. 3. It was found that clofazimine interacted with the synthetic single-stranded polynucleotide, poly G, whereas little interaction occurred withpoly A, poly C, or poly U. It was concluded that the guanine base region was a predominant site of clofazimine binding to DNA. 4. No evidence was found to indicate that clofazimine underwent intercalative binding between the base pairs of DNA. 5. It was proposed that clofazimine underwent binding along the minor groove region of DNA at appropriate base sequences which contain guanine. The resultant effect would inhibit template function of the DNA strand.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 798729

Source DB:  PubMed          Journal:  Int J Lepr Other Mycobact Dis        ISSN: 0148-916X


  9 in total

Review 1.  Systematic review of clofazimine for the treatment of drug-resistant tuberculosis.

Authors:  M Gopal; N Padayatchi; J Z Metcalfe; M R O'Donnell
Journal:  Int J Tuberc Lung Dis       Date:  2013-03-25       Impact factor: 2.373

2.  Molecular imaging of intracellular drug-membrane aggregate formation.

Authors:  Jason Baik; Gus R Rosania
Journal:  Mol Pharm       Date:  2011-08-12       Impact factor: 4.939

3.  Reduction of clofazimine by mycobacterial type 2 NADH:quinone oxidoreductase: a pathway for the generation of bactericidal levels of reactive oxygen species.

Authors:  Takahiro Yano; Sacha Kassovska-Bratinova; J Shin Teh; Jeffrey Winkler; Kevin Sullivan; Andre Isaacs; Norman M Schechter; Harvey Rubin
Journal:  J Biol Chem       Date:  2010-12-30       Impact factor: 5.157

4.  Anticancer efficacy and toxicokinetics of a novel paclitaxel-clofazimine nanoparticulate co-formulation.

Authors:  Dwayne Koot; Duncan Cromarty
Journal:  Drug Deliv Transl Res       Date:  2015-06       Impact factor: 4.617

Review 5.  Clinical pharmacokinetic considerations in the treatment of patients with leprosy.

Authors:  K Venkatesan
Journal:  Clin Pharmacokinet       Date:  1989-06       Impact factor: 6.447

6.  Effects of antituberculosis and antileprosy drugs on mycobacteriophage D29 growth.

Authors:  H L David; S Clavel; F Clement; J Moniz-Pereira
Journal:  Antimicrob Agents Chemother       Date:  1980-08       Impact factor: 5.191

7.  Targeting Pathological Tau by Small Molecule Inhibition of the Poly(A):MSUT2 RNA-Protein Interaction.

Authors:  Jeremy D Baker; Rikki L Uhrich; Timothy J Strovas; Aleen D Saxton; Brian C Kraemer
Journal:  ACS Chem Neurosci       Date:  2020-07-09       Impact factor: 4.418

8.  Production of Superoxide in Bacteria Is Stress- and Cell State-Dependent: A Gating-Optimized Flow Cytometry Method that Minimizes ROS Measurement Artifacts with Fluorescent Dyes.

Authors:  Megan E McBee; Yok H Chionh; Mariam L Sharaf; Peiying Ho; Maggie W L Cai; Peter C Dedon
Journal:  Front Microbiol       Date:  2017-03-21       Impact factor: 5.640

9.  Chemotherapeutic efficacies of a clofazimine and diminazene aceturate combination against piroplasm parasites and their AT-rich DNA-binding activity on Babesia bovis.

Authors:  Bumduuren Tuvshintulga; Mahmoud AbouLaila; Thillaiampalam Sivakumar; Dickson Stuart Tayebwa; Sambuu Gantuya; Khandsuren Naranbaatar; Aki Ishiyama; Masato Iwatsuki; Kazuhiko Otoguro; Satoshi Ōmura; Mohamad Alaa Terkawi; Azirwan Guswanto; Mohamed Abdo Rizk; Naoaki Yokoyama; Ikuo Igarashi
Journal:  Sci Rep       Date:  2017-10-24       Impact factor: 4.379

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.